Candel Therapeutics, Inc. announced on April 23, 2025, that an abstract was accepted for an oral presentation at the American Society of Clinical Oncology Annual Meeting about its phase 3 trial data for CAN-2409 in prostate cancer, scheduled for May 30 to June 3, 2025.